Skip to main content
Clinical Trials/CTRI/2012/11/003125
CTRI/2012/11/003125RecruitingPhase 2

Effect of oral administration of probiotic preparation VSL#3, a clinically safe mixture of 8 strains of viable live, lyophilized lactic acid bacteria, on the metabolic control in individuals with type-1 diabetes mellitus (T1DM); a randomized, double-blind, placebo controlled trial â?? A pilot study

CD Pharma India Pvt Ltd0 sites60 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Patients with T1DM
  • 18yrs of age or more(upto 65 yrs)
  • Duration of diabetes < 5 years

Exclusion Criteria

  • 1. Patients with any other forms of diabetes
  • 2. Pregnant and lactating women
  • 3. Patients with chronic renal or chronic liver disease
  • 4. Patients with any acute infective or systemic inflammatory illness
  • 5. Illiterate patients
  • 6. Patients unable to provide written informed consent
  • 7. Patients with serious diseases

Investigators

Similar Trials

Probiotic VSL#3 in patients with Type-1... | Clinical Trial